Policy Notices

• Notice of Policy Revision: Managing Conflicts of Interest for Requests for Applications (RFAs)
  (NOT-OD-21-005)
  National Institutes of Health
  

General Notices

• Notice of NCATS Interest in Receiving Letters Requesting Permission to Submit Applications to Support Annual Microphysiological Systems Scientific Conferences (U13)
  (NOT-TR-21-005)
  National Center for Advancing Translational Sciences
  

• Request for Information: Guidance on Current Research on the Prevention of Black Youth Suicide
  (NOT-MH-21-035)
  National Institute of Mental Health
  

Notice of Changes to Funding Opportunities

• Notice to Extend the Response Due Date for NOT-DA-20-073 "Request for Information (RFI):Advancing Biomarker Research and Implementation to Personalize Health Services Delivery for Tobacco Use Disorder"
  (NOT-DA-20-094)
  National Institute on Drug Abuse
  

• NEI Notice of Participation in PAR-19-093: "Leveraging Health Information Technology (Health IT) to Address Minority Health and Health Disparities (R01 Clinical Trial Optional)"
  (NOT-EY-21-002)
  National Eye Institute
  

• Change of the Award Project Period for PAR-18-950 and PAR-18-951 Opportunities for Collaborative Research at the NIH Clinical Center (X02 and U01)
  (NOT-HD-20-034)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Dental and Craniofacial Research
  National Institute of Neurological Disorders and Stroke
  

• Notice of NHLBI Participation in PA-20-227, "Administrative Supplements for Research on Dietary Supplements (Admin Supp Clinical Trial Not Allowed)"
  (NOT-HL-20-818)
  National Heart, Lung, and Blood Institute
  

• NIMHD Withdraws Participation in NOT-MH-20-047 "Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus"
  (NOT-MD-21-005)
  National Institute on Minority Health and Health Disparities
  

• NIMHD Withdraws Participation in NOT-MH-20-053 "Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19"
  (NOT-MD-21-006)
  National Institute on Minority Health and Health Disparities
  

• Notice of Change to Budget Information and Key Dates for PAR-20-026, "Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (U01 Clinical Trial Not Allowed)"
  (NOT-MH-21-015)
  National Institute of Mental Health
  

• RESCINDED - Notice of Change to Budget Information and Key Dates for PAR-20-027, "Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (Collaborative U01 Clinical Trial Not Allowed)"
  (NOT-MH-21-016)
  National Institute of Mental Health
  

• Notice of Extension to RFA-MH-18-700, "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)"
  (NOT-MH-21-020)
  National Institute of Mental Health
  

• Notice of Extension to RFA-MH-18-701, "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)"
  (NOT-MH-21-021)
  National Institute of Mental Health
  

• Notice of Extension to RFA-MH-18-702, "Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33- Clinical Trial Required)"
  (NOT-MH-21-022)
  National Institute of Mental Health
  

• Notice of Extension to RFA-MH-18-703, "Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)"
  (NOT-MH-21-023)
  National Institute of Mental Health
  

• Notice of Extension to RFA-MH-18-704, "Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33- Clinical Trial Required)"
  (NOT-MH-21-024)
  National Institute of Mental Health
  

• Notice of Extension to RFA-MH-18-705, "Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)"
  (NOT-MH-21-025)
  National Institute of Mental Health
  

• Notice of Extension to RFA-MH-18-706, "Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)"
  (NOT-MH-21-026)
  National Institute of Mental Health
  

• Notice of Extension to RFA-MH-18-707, "Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required"
  (NOT-MH-21-027)
  National Institute of Mental Health
  

• Notice to Extend the Response Date for NOT-MH-20-073, "Request for Information (RFI): Fostering Innovative Research to Improve Mental Health Outcomes Among Minority and Health Disparities Populations"
  (NOT-MH-21-060)
  National Institute of Mental Health
  

• Notice of Change to PAR-19-315 "Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)"
  (NOT-NS-21-010)
  National Institute of Neurological Disorders and Stroke
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional)
  (NOT-MH-21-005)
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Institute on Drug Abuse
  

Notices of Special Interest

• Notice of Special Interest: Integrative Studies of Neural Mechanisms Underlying Fundamental Affective Processes in Aging
  (NOT-AG-21-012)
  National Institute on Aging
  

• Notice of Special Interest (NOSI): Administrative Supplements for Minor Alterations and Renovations to Advance Ongoing HIV/AIDS Research Projects Supported by the NIMHD RCMI Program or the NIGMS IDeA and NARCH Programs
  (NOT-MD-21-004)
  National Institute on Minority Health and Health Disparities
  National Institute of General Medical Sciences
  Office of AIDS Research
  

Funding Opportunities

• Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
  (PA-20-272)
  National Institutes of Health
  John E. Fogarty International Center
  National Center for Advancing Translational Sciences
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Biomedical Imaging and Bioengineering
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  National Library of Medicine
  Office of Behavioral and Social Sciences Research
  Office of Research on Women's Health
  Application Receipt Date(s): Due dates may vary by awarding IC. See the awarding ICs web site or applicable Notice of Special Interest (NOSI) for appropriate Application Due Dates. Applicants may also contact their respective awarding IC. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
  (PAR-20-313)
  National Cancer Institute
  Application Receipt Date(s): February 18, 2021; July 9, 2021; October 8, 2021; February 14, 2022; July 11, 2022; October 11, 2022; February 14, 2023; July 10, 2023; October 10, 2023
  
  

• Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
  (PAR-20-314)
  National Cancer Institute
  Application Receipt Date(s): February 18, 2021; July 9, 2021; October 8, 2021; February 14, 2022; July 11, 2022; October 11, 2022; February 14, 2023; July 10, 2023; October 10, 2023
  
  

• Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21 Clinical Trial Not Allowed)
  (PAR-21-028)
  National Institute of Mental Health
  National Eye Institute
  National Institute on Aging
  National Institute on Drug Abuse
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is February 16, 2021.
  
  

• Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
  (PAR-21-029)
  National Institute of Mental Health
  National Eye Institute
  National Institute on Aging
  National Institute on Drug Abuse
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is February 5, 2021.
  
  

• NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)
  (PAR-21-032)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): February 11, 2021, June 9, 2021, October 14, 2021, February 9, 2022, June 8, 2022, October 11, 2022, February 9, 2023, June 8, 2023, and October 10, 2023.
  
  

• NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed)
  (PAR-21-046)
  National Library of Medicine
  Application Receipt Date(s): February 26, 2021, February 24, 2022 and February 24, 2023.
  
  

• Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource Core (U24) (Clinical Trial Optional)
  (RFA-AA-20-011)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): May 26, 2021
  
  

• Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24) (Clinical Trial Optional)
  (RFA-AA-20-012)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): May 26, 2021
  
  

• Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia (U01 Clinical Trial Optional)
  (RFA-AA-20-013)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): May 26, 2021
  
  

• New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not Allowed)
  (RFA-CA-20-049)
  National Cancer Institute
  National Institute of Environmental Health Sciences
  Application Receipt Date(s): January 29, 2021 No late application will be accepted for this Funding Opportunity Announcement.
  
  

• New Cohorts for Environmental Exposures and Cancer Risk (CEECR) Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-CA-20-050)
  National Cancer Institute
  National Institute of Environmental Health Sciences
  Application Receipt Date(s): January 29, 2021 No late application will be accepted for this Funding Opportunity Announcement.
  
  

• Collaborative Approaches to Engineer Biology for Cancer Applications (U01 Clinical Trial Not Allowed)
  (RFA-CA-20-054)
  National Cancer Institute
  National Institute of Biomedical Imaging and Bioengineering
  Application Receipt Date(s): January 15, 2021 No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• Elucidation of mechanisms underlying complex morbidities of SUD and other mental Illnesses in people living with HIV/AIDS (R01 Clinical Trial Optional)
  (RFA-DA-21-012)
  National Institute on Drug Abuse
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
  
  

• Utilizing In Vitro Functional Genomics Advances for Gene-Environment (G x E) Discovery and Validation (R01 Clinical Trial Not Allowed)
  (RFA-ES-20-018)
  National Institute of Environmental Health Sciences
  National Cancer Institute
  National Human Genome Research Institute
  Application Receipt Date(s): February 1, 2021
  
  

• From Genomic Association to Causation: A Convergent Neuroscience Approach to Linking Levels of Analysis for Understanding Neuropsychiatric Disorders (U19 Clinical Trial Optional)
  (RFA-MH-21-165)
  National Institute of Mental Health
  Application Receipt Date(s): March 17, 2021 No late applications will be accepted for this Funding Opportunity Announcement. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date